References
- Zitvogel L, Apetoh L, Ghiringhelli F, Andre F, Tesniere A, Kroemer G. The anticancer immune response: indispensable for therapeutic success?. J Clin Invest 2008;118:1991–2001.
- Disis ML, Bernhard H, Jaffee EM. Use of tumour-responsive T cells as cancer treatment. Lancet 2009;373:673–83.
- Slingluff CL Jr, Engelhard VH, Ferrone S. Peptide and dendritic cell vaccines. Clin Cancer Res 2006;12:2342–5.
- Keilholz U, Martus P, Scheibenbogen C. Immune monitoring of T-cell responses in cancer vaccine development. Clin Cancer Res 2006;12:2346–52.
- Dudley ME, Wunderlich JR, Yang JC, Sherry RM, Topalian SL, Restifo NP, . Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma. J Clin Oncol 2005;23:2346–57.
- Dudley ME, Wunderlich JR, Shelton TE, Even J, Rosenberg SA. Generation of tumor-infiltrating lymphocyte cultures for use in adoptive transfer therapy for melanoma patients. J Immunother 2003;26:332–42.
- Kondo M, Sakuta K, Noguchi A, Ariyoshi N, Sato K, Sato S, . Zoledronate facilitates large-scale ex vivo expansion of functional gammadelta T cells from cancer patients for use in adoptive immunotherapy. Cytotherapy 2008;10:842–56.
- Fischer K, Andreesen R, Mackensen A. An improved flow cytometric assay for the determination of cytotoxic T lymphocyte activity. J Immunol Methods 2002;259:159–69.
- Mesler Muul L, Nason-Burchenal K, Hyatt C, Schwarz S, Slavin D, Director EP, . Studies of serum-free culture medium in the generation of lymphokine activated killer cells. J Immunol Methods 1987;105:183–92.
- Jadus MR, Thurman GB, Mrowca-Bastin A, Yannelli JR. The generation of human lymphokine-activated killer cells in various serum-free media. J Immunol Methods 1988;109:169–74.
- Uenaka A, Wada H, Isobe M, Saika T, Tsuji K, Sato E, . T cell immunomonitoring and tumor responses in patients immunized with a complex of cholesterol-bearing hydrophobized pullulan (CHP) and NY-ESO-1 protein. Cancer Immun 2007;7:9.
- Flescher E, Fingrut O. Suppression of interleukin 2 biosynthesis by three modes of oxidative cellular stress: selective prevention by N-acetyl cysteine. Cytokine 2000;12:495–8.
- Yim CY, Hibbs JB Jr, McGregor JR, Galinsky RE, Samlowski WE. Use of N-acetyl cysteine to increase intracellular glutathione during the induction of antitumor responses by IL-2. J Immunol 1994;152:5796–805.
- Park CS, Park WR, Sugimoto N, Nakahira M, Ahn HJ, Hamaoka T, . Differential effects of N-acetyl-l-cysteine on IL-2- vs IL-12-driven proliferation of a T cell clone: implications for distinct signalling pathways. Cytokine 2000;12:1419–22.
- Kalamasz D, Long SA, Taniguchi R, Buckner JH, Berenson RJ, Bonyhadi M. Optimization of human T-cell expansion ex vivo using magnetic beads conjugated with anti-CD3 and anti-CD28 antibodies. J Immunother 2004;27:405–18.